Shots: The approval is based on non-inferiority data assessing Hyrimoz vs reference biologic in patients with rheumatoid arthritis, plaque psoriasis, Crohn’s disease, uveitis and ulcerative colitis The study demonstrated in […]readmore
Shots: Keytruda sold $1.67Bn, 90% Y-o-Y, narrowly beating Opdivo’s $1.63Bn in Q2’18 Higher sales are observed as Keytruda in combination with Lilly’s Alimta and platinum chemo improves OS with 51% […]readmore
Shots: Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer) Marketed as 150mg and 440mg multiple dose vials As […]readmore
Shots: The drug failed to meet the primary endpoint of thyroid cancer lead to its failure as well as removal from phase 3, double blind involved in high risk DTC […]readmore
Shots: With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety To identify specific subgroups population to develop targeted treatments GSK is initially […]readmore
Shots: The approval is based on P-I AG120-C-011 (NCT02074839) study results assessing Tibsovo (ivosidenib, 500mg) in 174 patients with r/r AML and IDH1 mutation aged 67 yrs. P-I AG120-C-011 study […]readmore
Shots: The approval is based on Detective Part 1 & Part 2 (TAF112582) and Gather (TAF116564) studies results assessing Krintafel (tafenoquine, 300mg) in 800 patients with relapse P.vivax malaria The […]readmore
Shots: The approval is based on non-inferiority data demonstrating biosimilarity between Nivestym and the reference product, Neupogen (filgrastim) Pfizer has received the US FDA’s fourth approvals for its biosimilar including […]readmore
Shots: The approval is based on 12 clinical trials results assessing TPOXX (tecovirimat) in 700 patients, demonstrating no adverse effects ’ TPOXX (tecovirimat) receives 17-0 votes from FDA’s Antimicrobial Drug […]readmore
Shots: The approval is based on P-III EPIC (Evaluating Plazomicin in cUTI) study results assessing Zemdri (plazomicin, IV) vs Meropenem in 388 patients with cUTI including pyelonephritis aged ≥18 yrs. […]readmore